Edgewise Therapeutics, Inc. (EWTX)

20.34 +0.82 (+4.20%) At close: 04:00PM EDT

Edgewise Therapeutics, Inc.

1715 38th Street
Boulder, CO 80301
United States
720 262 7002
https://www.edgewisetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 88

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter A. Thompson FACP, M.D.	Co-Founder & Independent Chairman	76k	N/A	1960
Dr. Kevin Koch Ph.D.	President, CEO & Director	905.52k	N/A	1960
Dr. Badreddin Edris Ph.D.	Co-Founder & Independent Director	43k	N/A	1987
Dr. Behrad Derakhshan Ph.D.	Chief Business Officer	630.67k	N/A	1980
Dr. Joanne M. Donovan M.D., Ph.D.	Chief Medical Officer	696.4k	N/A	1957
Dr. Alan J. Russell Ph.D.	Co-Founder, Chief Scientific Officer & Director	657.52k	N/A	1970
Mr. R. Michael Carruthers	Chief Financial Officer	386.01k	N/A	1958
Mr. John R. Moore	General Counsel	N/A	N/A	1964
Dr. Marc Semigran M.D.	Chief Development Officer	N/A	N/A	1957

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Corporate Governance

Edgewise Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.